1
|
Lai C, Lin C, Su Y, Shih Y, Wang C, Teng CJ, Chou C. Survival outcomes of patients with head and neck squamous cell cancer with hepatitis B virus infection: An analysis from an endemic tertiary center. Cancer Med 2022; 12:6802-6810. [PMID: 36426417 PMCID: PMC10067106 DOI: 10.1002/cam4.5469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2022] [Revised: 10/30/2022] [Accepted: 11/13/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Hepatitis B virus (HBV) affects the occurrence and survival outcome of various malignant disorders. The study aimed to evaluate the survival outcome of head and neck squamous cell cancer (HNSCC) patients with or without HBV infection. METHODS This study included patients with HNSCC who visited Taichung Veterans General Hospital from 2007 to 2015. HBV infection was defined by hepatitis B surface antigen (HBsAg) seropositivity. By propensity score matching, we compared survival outcomes, including progression-free survival (PFS) and overall survival (OS), among patients with or without HBV infection. RESULTS The prevalence of HBV infection in our cohort was 12.3%. Among the 1,015 patients included in the matched analysis, a higher risk of baseline liver cirrhosis (11.3% vs. 3.4%, p < 0.001) and initial hepatic dysfunction (10.8% vs. 5.4%, p = 0.005) rates were observed than those without HBV infection at baseline. The 5-year OS was 43.1% and 53.2% (p < 0.001) and the 5-year PFS was 37.4% and 42.3% (p = 0.007) in patients with and without HBV infection, respectively. The incidence of subsequent hepatic dysfunction showed no difference between patients with and without HBV infection (29.6% vs. 26.8%, p = 0.439). CONCLUSIONS Patients with HNSCC and HBV infection were younger and had a higher risk of cirrhosis compared to those without HBV infection. Moreover, HBV infection significantly influenced the OS and PFS outcomes but not subsequent hepatic dysfunction in patients with HNSCC.
Collapse
Affiliation(s)
- Cheng‐Lun Lai
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
| | - Cheng‐Hsien Lin
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
| | - Yu‐Chen Su
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
| | - Yu‐Hsuan Shih
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
- Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan
| | - Chen‐Chi Wang
- School of Medicine National Yang Ming Chiao Tung University Taichung Taiwan
- School of Speech Language Pathology & Audiology Chung Shan Medical University Taichung Taiwan
- Department of Audiology and Speech‐Language Pathology Asia University Taichung Taiwan
- Department of Otolaryngology‐Head & Neck Surgery Taichung Veterans General Hospital Taichung Taiwan
| | - Chieh‐Lin Jerry Teng
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
- Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan
- Department of Life Science Tunghai University Taichung Taiwan
- School of Medicine Chung Shan Medical University Taichung Taiwan
| | - Cheng‐Wei Chou
- Division of Hematology/Medical Oncology, Department of Medicine Taichung Veterans General Hospital Taichung Taiwan
- Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taipei Taiwan
- Graduate Institute of Biomedical Sciences China Medical University Taichung Taiwan
| |
Collapse
|
2
|
Yue Y, Liang J, Wu Y, Tong W, Li D, Cao X, Wang X. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer. Technol Cancer Res Treat 2022; 21:15330338221132669. [PMID: 36254567 PMCID: PMC9580102 DOI: 10.1177/15330338221132669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Background: Luminal B-like human epidermal growth factor receptor 2 negative (Luminal B [HER2-]) is the most common molecular subtype of breast cancer (BC). Since the relationship between Luminal B (HER2-) BC and liver metastasis (LM) is poorly defined, this retrospective study aimed to develop an LM risk nomogram for patients with lymph node-related (N + Luminal B [HER2-]) BC. Methods: Data were obtained for patients initially diagnosed with BC from the Tianjin Medical University Cancer Institute and Hospital. There were 30,975 Chinese female patients with stage I-III BC and follow-up confirming 1217 subsequent patients with LM, and 427 patients with N + Luminal B (HER2-). The LM risk was assessed using Cox proportional hazards regression, histogram, Venn diagram, and Kaplan-Meier survival analysis, with further analysis for patients with N + Luminal B (HER2-) BC. A nomogram was established based on the N + Luminal B (HER2-) BC data, which was validated using calibration plots. Results: The median age of 427 patients with N + Luminal B (HER2-) liver metastasis of breast cancer (BCLM) was 49 years. The largest number of patients with BCLM was diagnosed between the second to the 6th year, the longest interval from initial BC diagnosis to subsequent LM was 145 months. The patients with LM as the first site of distant metastasis which is associated with better survival were analyzed by Kaplan-Meier. The nomogram was constructed for the risk of LM that included age, menstrual status, unilateral oophorectomy, pregnancy, hepatitis B antigen, region of residence, tumor size, lymph node, clavicular lymph nodes, progesterone receptor, and lymph vessel invasion. Conclusion: We described the clinicopathological characteristics of patients with stage I-III BC, and constructed a nomogram for calculating personalized LM probabilities for patients with N + Luminal B (HER2-), which could guide future prolonged or early extensive treatment decisions.
Collapse
Affiliation(s)
- Yuhan Yue
- First Department of Breast cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China,Department of Breast Tumor Center, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China
| | - Junqing Liang
- Department of Breast Tumor Center, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China,Department of cytotherapy for tumors, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China
| | - Yuruo Wu
- Department of cytotherapy for tumors, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China
| | - Weibing Tong
- Department of Breast Tumor Center, Affiliated People's Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China
| | - Dan Li
- First Department of Breast cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China
| | - Xuchen Cao
- First Department of Breast cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China
| | - Xin Wang
- First Department of Breast cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China,Xin Wang, First Department of Breast cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, China.
| |
Collapse
|
3
|
Zhang N, Tao D, Lei H, Shao Q, Liu Y, Long H, Zeng X. HBV Infection Status Does Not Influence the Initial Metastatic Pattern and the Prognosis of Breast Cancer Patients with de novo and Relapsed Metastatic Disease. J Inflamm Res 2022; 15:2509-2521. [PMID: 35479830 PMCID: PMC9038213 DOI: 10.2147/jir.s355301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 04/13/2022] [Indexed: 11/23/2022] Open
Affiliation(s)
- Ningning Zhang
- Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
| | - Dan Tao
- Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
| | - Haike Lei
- Department of Appointment and Follow-up Center, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
| | - Qing Shao
- Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
| | - Yumin Liu
- Department of Medical Record, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
| | - Hua Long
- Department of Medical Record, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
| | - Xiaohua Zeng
- Department of Breast Cancer Center, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China
- Correspondence: Xiaohua Zeng, Department of Breast Cancer Center, Chongqing University Cancer Hospital, 181 Han Yu Road, Shapingba District, Chongqing, 400030, People’s Republic of China, Tel/Fax +86-23-65310859, Email
| |
Collapse
|